Table 9.
Treatment groups | SOD (U/mg protein) | GPx (U/mg protein) | CAT (U/mg protein) | GSH (µmol/g tissue) | MDA (nmol/g tissue) |
---|---|---|---|---|---|
NC | 52.4 ± 3.18b, c | 6.6 ± 0.61b, c | 11.3 ± 0.92b, c | 9.6 ± 0.71b, c | 25.6 ± 1.15b, c |
DC (STZ) | 24.8 ± 1.80a | 1.9 ± 0.12a | 4.8 ± 0.22a | 3.5 ± 0.22a | 43.1 ± 2.85a |
GLB | 29.2 ± 2.84a, b | 3.0 ± 0.28a, b | 5.7 ± 0.42a, b | 5.4 ± 0.29a, b | 33.6 ± 2.36a, b |
MCFE-250 | 36.1 ± 1.96a, b | 3.1 ± 0.29a, b | 6.4 ± 0.33a, b | 5.8 ± 0.33a, b | 32.4 ± 2.14a, b |
MCFE-500 | 37.5 ± 3.39a, b | 3.3 ± 0.38a, b | 6.9 ± 0.48a, b | 6.0 ± 0.48a, b | 31.7 ± 2.11a, b |
GLB + MCFE-250 | 39.0 ± 2.80a, b | 3.4 ± 0.39a, b | 7.3 ± 0.64a, b | 6.1 ± 0.58a, b | 30.8 ± 2.00a, b |
GLB + MCFE-500 | 43.8 ± 2.89b, c | 3.6 ± 0.47b, c | 8.8 ± 0.72b, c | 6.5 ± 0.60b, c | 26.5 ± 2.01b, c |
Values are expressed as mean ± SE (n = 6).
Multiple group comparisons were performed by analysis of variance (ANOVA) followed by Tukey’s multiple comparison post hoc test at p ≤ 0.05.
P ≤ 0.05, statistically significant from the normal control (NC) group.
P ≤ 0.05, statistically significant from the diabetic control (DC) group.
P ≤ 0.05, statistically significant from GLB group.